WFRF:(Haukaas S)
Search: WFRF:(Haukaas S) > Parenteral estrogen...
- 3 of 4
- Previous record
- Next record
- To hitlist
Parenteral estrogen versus combined androgen deprivation in the treatment of metastatic prostatic cancer : Part 2. Final evaluation of the Scandinavian Prostatic Cancer Group (SPCG) Study No. 5
- Hedlund, P. O. (author)
- Damber, J. E. (author)
-
- Hagerman, I. (author)
- Karolinska Institutet
- show more...
- Haukaas, S (author)
- Iversen, P. (author)
- Johansson, R. (author)
- Klarskov, P (author)
- Lundbeck, F. (author)
- Rasmussen, F. (author)
- Viitanen, J. (author)
- show less...
- (creator_code:org_t)
- 2009-07-09
- 2008
- English.
- In: Scandinavian Journal of Urology and Nephrology. - : Informa UK Limited. - 0036-5599 .- 1651-2065. ; 42:3, s. 220-229
- Journal article (peer-reviewed)
Abstract
Subject headings
Close
- Objective. To compare parenteral estrogen therapy in the form of high-dose polyestradiol phosphate (PEP, Estradurin®) with combined androgen deprivation (CAD) in the treatment of prostate cancer patients with skeletal metastases. The aim of the study was to compare anticancer efficacy and adverse events, especially cardiovascular events. Material and methods. In total, 910 eligible patients with T0-4, NX, M1, G1-3 prostate cancer with an Eastern Cooperative Oncology Group performance status of 0-2 were randomized to treatment with either PEP 240mg i.m. twice a month for 2months and thereafter monthly, or flutamide (Eulexin®) 250mg t.i.d. per os in combination with either triptorelin (Decapeptyl®) 3.75mg i.m. per month or on an optional basis bilateral orchidectomy. Results. At this final evaluation of the trial 855 of the 910 patients were dead. There was no difference between the treatment groups in terms of biochemical or clinical progression-free survival or in overall or disease-specific survival. There was no difference in cardiovascular mortality, but a significant increase in non-fatal cardiovascular events in the PEP arm (p<0.05) predominantly caused by an increase in ischemic heart and heart decompensation events. There were 18 grave skeletal events in the CAD group but none in the PEP group (p=0.001). Conclusions. PEP has an anticancer efficacy equal to CAD and does not increase cardiovascular mortality in metastasized patients, but carries a significant risk of non-fatal cardiovascular events, which should be balanced against the skeletal complications in the CAD group. It is feasible to use Estradurin in the primary or secondary endocrine treatment of metastasized patients without prominent cardiac risk factors and especially those with osteoporosis. © 2008 Taylor & Francis.
Keyword
- MEDICINE
- MEDICIN
Publication and Content Type
- ref (subject category)
- art (subject category)
Find in a library
- Scandinavian Journal of Urology and Nephrology (Search for host publication in LIBRIS)
To the university's database
- 3 of 4
- Previous record
- Next record
- To hitlist
Find more in SwePub
- By the author/editor
- Hedlund, P. O.
- Damber, J. E.
- Hagerman, I.
- Haukaas, S
- Henriksson, P.
- Iversen, P.
- show more...
- Johansson, R.
- Klarskov, P
- Lundbeck, F.
- Rasmussen, F.
- Varenhorst, Eber ...
- Viitanen, J.
- Stattin, Pär
- show less...
- Articles in the publication
- Scandinavian Jou ...
- By the university
- Linköping University
- Umeå University
- Karolinska Institutet
Search outside SwePub
- Extend your search to:
- Google Book Search
- Google Scholar
Kungliga biblioteket hanterar dina personuppgifter i enlighet med EU:s dataskyddsförordning (2018), GDPR. Läs mer om hur det funkar här.
Så här hanterar KB dina uppgifter vid användning av denna tjänst.
- Copyright © LIBRIS - National Library Systems
- LIBRIS.kb.se
